尹建坤;刘世刚;李光熙;

• 1:北京中医药大学
• 2:中国中医科学院广安门医院呼吸科

摘要(Abstract)：

特发性肺纤维化是一种原因不明、具有不可逆肺纤维化特征的间质性肺疾病，因病因不明、诊断困难、预后不良、易感染加重是目前国内外诊疗及研究的难点。李光熙教授根据多年临床经验，认为该病属中医“肺痿”范畴。肺肾亏虚、正气不足为致病之本，痰浊瘀血、痹阻肺络为发病之标，本虚标实，病程绵延，反复不愈。中医治疗本病以补益肺肾、宣通肺气、化痰祛瘀为法。

关键词(KeyWords)： 特发性肺纤维化;中医药;病机

Abstract:

Keywords:

基金项目(Foundation): 中央本级重大增减支项目：名贵中药资源可持续利用能力建设项目(2060302)

作者(Authors): 尹建坤;刘世刚;李光熙;

DOI: 10.13463/j.cnki.jlzyy.2022.03.007

参考文献(References)：

• [1]NATSUIZAKA M,CHIBA H,I,KURONUMA K,et al.Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences[J].American Journal of Respiratory and Critical Care Medicine,2014(7):9-773.
• [2]YIN W L,HAN J,ZHANG Z J,et al.Aloperine protects mice against bleomycin-induced pulmonary fibrosis by attenuating fibroblast proliferation and differentiation[J].Scientific Reports,2018(1):6265.
• [3]杨伟强,赵峰.特发性肺纤维化发病机制的研究进展[J].医学综述,2020,26(9):1684-1689,1695.
• [4]李振华.特发性肺间质纤维化诊治进展[J].中国实用内科杂志,2020,40(5):353-356.
• [5]WOLLIN L,WEX E,PAUTSCH A,et al.Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis[J].The European Respiratory Journal,2015(5):45-1434.
• [6]HOSTETTLER K E,ZHONG J,PAPAKONSTANTINOU E,et al.Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis[J].Respiratory Research,2014:157.
• [7]SPRUIT M A,SINGH S J,GARVEY C,et al.An official American Thoracic Society/European Respiratory Society statement:key concepts and advances in pulmonary rehabilitation[J].American Journal of Respiratory and Critical Care Medicine,2013(8):0-64.
• [8]KOZU R,SENJYU H,JENKINS S C,et al.Differences in response to pulmonary rehabilitation in idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease[J].Respiration,2010:196-205.
• [9]KEATING D,LEVVEY B,KOTSIMBOS T,et al.Lung transplantation in pulmonary fibrosis:challenging early outcomes counterbalanced by surprisingly good outcomes beyond 15 years[J].Transplantation Proceedings,2009,41(1):289-291.